Join host Flo Lumsden as she sits down with John Cumbers, CEO and founder of SynBioBeta, at the world's largest synthetic biology conference this past May. In this conversation, John shares how AI is fundamentally reshaping the field of biology — from large language models designing novel enzymes and antibodies to full-stack scientific innovation.
Discover the most exciting breakthroughs happening right now, including xenotransplantation with humanized pig organs, consumer biotech products like probiotic hangover cures, and genetically engineered glowing plants. John also reveals what he's most excited about at the intersection of AI and biotech, the challenges that lie ahead, and why he believes we're approaching AGI (Artificial General Intelligence).
Plus, learn the origin story of SynBioBeta — how a small meeting of 150 people in a law firm grew into a 2,000+ person conference with over 100 exhibitors and sponsors — and why creating community and "paying it forward" is at the heart of everything he does.
Outline with Timecodes:
00:00 - Introduction & Podcast Overview
00:36 - SynBioBeta Origin Story
02:17 - John Cumbers, CEO & Founder Introduction
02:23 - Evolution of SynBioBeta: From 150 to 2,000+ Attendees
02:57 - John's Passion for Event Production & Community Building
03:42 - "Paying It Forward" Culture & Success Stories
04:31 - Science as a Competitive Advantage for Startups
05:18 - AI at the Intersection of Biotech
05:30 - Large Language Models for Genes and Genomes
06:22 - How AI is Designing Novel Enzymes & Organisms
07:03 - Antibody Development for Drug Discovery
07:14 - Challenges & Limitations of AI Implementation
08:09 - Healthcare Innovations: Xenotransplantation
08:55 - Consumer Biotech Applications
09:03 - Zbiotics & Probiotic Products
09:18 - GLP-1 Peptides & Cellular Reprogramming
10:17 - New Innovations: Glowing Plants & Hardware/Software Tools
11:04 - Full-Stack AI Integration in Biotech
12:12 - SynBioBeta 2026 Themes & Community Sessions
13:00 - Closing Remarks
Discover the most exciting breakthroughs happening right now, including xenotransplantation with humanized pig organs, consumer biotech products like probiotic hangover cures, and genetically engineered glowing plants. John also reveals what he's most excited about at the intersection of AI and biotech, the challenges that lie ahead, and why he believes we're approaching AGI (Artificial General Intelligence).
Plus, learn the origin story of SynBioBeta — how a small meeting of 150 people in a law firm grew into a 2,000+ person conference with over 100 exhibitors and sponsors — and why creating community and "paying it forward" is at the heart of everything he does.
Outline with Timecodes:
00:00 - Introduction & Podcast Overview
00:36 - SynBioBeta Origin Story
02:17 - John Cumbers, CEO & Founder Introduction
02:23 - Evolution of SynBioBeta: From 150 to 2,000+ Attendees
02:57 - John's Passion for Event Production & Community Building
03:42 - "Paying It Forward" Culture & Success Stories
04:31 - Science as a Competitive Advantage for Startups
05:18 - AI at the Intersection of Biotech
05:30 - Large Language Models for Genes and Genomes
06:22 - How AI is Designing Novel Enzymes & Organisms
07:03 - Antibody Development for Drug Discovery
07:14 - Challenges & Limitations of AI Implementation
08:09 - Healthcare Innovations: Xenotransplantation
08:55 - Consumer Biotech Applications
09:03 - Zbiotics & Probiotic Products
09:18 - GLP-1 Peptides & Cellular Reprogramming
10:17 - New Innovations: Glowing Plants & Hardware/Software Tools
11:04 - Full-Stack AI Integration in Biotech
12:12 - SynBioBeta 2026 Themes & Community Sessions
13:00 - Closing Remarks